hydroxyurea has been researched along with Cancer of Skin in 77 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 68-year-old women with polycythemia vera was treated with hydroxyurea for 8 years and developed painful ulcers on her lower legs, multiple hypertrophic actinic keratoses and a squamous cell carcinoma." | 7.75 | [Cutaneous side effects of hydroxyurea treatment for polycythemia vera]. ( Akanay-Diesel, S; Hanneken, S; Hoff, NP; Pippirs, U; Schulte, KW, 2009) |
| "Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treatment in B16 melanoma cells." | 5.62 | Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p. ( Gao, Y; Han, DX; Huang, YJ; Jiang, H; Wang, CJ; Wang, WH; Yuan, B; Zhang, JB; Zheng, Y, 2021) |
| "Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs)." | 5.40 | Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. ( Antar, A; El-Majzoub, N; Ghosn, S; Ishak, RS; Mahfouz, R; Otrock, ZK; Taher, AT, 2014) |
| "Hydroxyurea (HU) has been shown to induce a variety of cutaneous adverse reactions, including severe leg ulcers." | 3.78 | A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma. ( Berger, A; Blumberg, S; Chen, W; McMeeking, A; O'Neill, D; Pastar, I; Ross, F; Stone, T, 2012) |
| " The patient was on long-term therapy with hydroxyurea (HU) for polycythemia vera." | 3.77 | Concurrent basal cell and squamous cell carcinomas associated with hydroxyurea therapy. ( Batinac, T; Hadžisejdić, I; Jonjić, N; Načinović-Duletić, A; Radić, J; Valković, T, 2011) |
| "A 68-year-old women with polycythemia vera was treated with hydroxyurea for 8 years and developed painful ulcers on her lower legs, multiple hypertrophic actinic keratoses and a squamous cell carcinoma." | 3.75 | [Cutaneous side effects of hydroxyurea treatment for polycythemia vera]. ( Akanay-Diesel, S; Hanneken, S; Hoff, NP; Pippirs, U; Schulte, KW, 2009) |
| "Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation." | 3.74 | Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. ( Chimenti, S; Saraceno, R; Teoli, M, 2008) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| " However, these agents also place patients at increased risk for drug-related cutaneous adverse events." | 2.66 | Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. ( Guglielmelli, P; Malato, A; Palumbo, GA; Pugliese, N; Rossi, E, 2020) |
| " A dose-response relationship for the UV-induced DNA repair synthesis was established for each individual." | 2.64 | Ultraviolet-induced dna repair synthesis in lymphocytes from patients with actinic keratosis. ( Lambert, B; Ringborg, U; Swanbeck, G, 1976) |
| "Nonmelanoma skin cancer is the most common malignant tumor in the fair skin population, with each year several millions of diagnosed cases." | 2.61 | Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience. ( Cantisani, C; Cantoresi, F; Carmosino, I; Cartoni, C; Kiss, N; Naqeshbandi, AF; Tofani, S; Tosti, G, 2019) |
| "Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treatment in B16 melanoma cells." | 1.62 | Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p. ( Gao, Y; Han, DX; Huang, YJ; Jiang, H; Wang, CJ; Wang, WH; Yuan, B; Zhang, JB; Zheng, Y, 2021) |
| "Hydroxyurea is an antimetabolite primarily used to treat myeloproliferative disorders, and chronic treatment is associated with many cutaneous adverse effects ranging in severity from ichthyosis to aggressive nonmelanoma skin cancer." | 1.46 | A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea. ( Aires, D; Neill, B; Neill, J; Rajpara, A; Ryser, T, 2017) |
| "Non-melanoma skin cancers were reported in 51 patients (27%)." | 1.40 | Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. ( Forsyth, C; Grigg, A; Verner, E, 2014) |
| "Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs)." | 1.40 | Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. ( Antar, A; El-Majzoub, N; Ghosn, S; Ishak, RS; Mahfouz, R; Otrock, ZK; Taher, AT, 2014) |
| "The chloromas are regarded as an early herald of a systemic relapse, rather than as a localised process." | 1.39 | Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase. ( Chaudhary, SC; Jain, N; Kumar, V; Mishra, S, 2013) |
| " However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available." | 1.38 | Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. ( Antonioli, E; Baccarani, M; Barbui, T; Bertozzi, I; Bosi, A; Cacciola, E; Cacciola, R; Cazzola, M; De Stefano, V; Elli, E; Finazzi, G; Finazzi, M; Guglielmelli, P; Luigia Randi, M; Martinelli, V; Passamonti, F; Pieri, L; Pogliani, E; Rambaldi, A; Rodeghiero, F; Rossi, E; Ruggeri, M; Rumi, E; Vannucchi, AM; Vianelli, N; Za, T, 2012) |
| "Skin cancer is the most common cancer, and often occurs in the head and neck region." | 1.35 | Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009) |
| "Hydroxyurea is a ribonucleotide diphosphate reductase inhibitor used in the treatment of patients with myeloproliferative disorders." | 1.32 | Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy. ( Altaner, S; Demir, M; Pamuk, GE; Tek, M; Turgut, B; Vural, O, 2003) |
| "Squamous cell carcinomas are the most severe among them." | 1.31 | [Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]. ( Estève, E; Georgescu, V; Heitzmann, P; Martin, L, 2001) |
| "Since squamous cell carcinoma is a malignant cutaneous neoplasm that can metastatize, the surveillance of skin changes is advisable during hydroxyurea treatment." | 1.30 | Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. ( De Simone, C; Guerriero, C; Guidi, B; Rotoli, M; Tartaglione, R; Venier, A, 1998) |
| "The association of multiple cutaneous cancers and long-term use of hydroxyurea is now being recognized." | 1.30 | Multiple skin cancers associated with hydroxyurea therapy. ( Best, PJ; Petitt, RM, 1998) |
| "A 67-year-old patient with chronic myeloid leukemia for 4 years rapidly developed multiple squamous-cell carcinomas on the scalp." | 1.29 | Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia. ( Andrac, L; Angeli-Besson, C; Jacquet, P; Koeppel, MC; Sayag, J, 1995) |
| "Multiple lesions of Bowen's disease and squamous cell carcinoma on the penis and pubic areas developed in a 32-year-old patient with psoriasis who was undergoing treatment with psoralen and long-wave ultraviolet radiation (PUVA)." | 1.26 | Bowen's disease and squamous cell carcinoma. Occurrence in a patient with psoriasis after topical, systemic, and PUVA therapy. ( Tam, DW; Urbach, F; Van Scott, EJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (42.86) | 18.7374 |
| 1990's | 11 (14.29) | 18.2507 |
| 2000's | 9 (11.69) | 29.6817 |
| 2010's | 14 (18.18) | 24.3611 |
| 2020's | 10 (12.99) | 2.80 |
| Authors | Studies |
|---|---|
| Sekhri, R | 1 |
| Sadjadian, P | 1 |
| Becker, T | 1 |
| Kolatzki, V | 1 |
| Huenerbein, K | 1 |
| Meixner, R | 1 |
| Marchi, H | 1 |
| Wallmann, R | 1 |
| Fuchs, C | 1 |
| Griesshammer, M | 1 |
| Wille, K | 1 |
| Rubin, A | 1 |
| Haroon, A | 1 |
| Rao, BK | 1 |
| Firoz, BF | 1 |
| Torre, EA | 1 |
| Kersh, AE | 1 |
| Fischer, AS | 1 |
| Xu, X | 1 |
| Rosenbach, M | 1 |
| Shields, BE | 1 |
| Gambichler, T | 1 |
| Stockfleth, E | 1 |
| Susok, L | 1 |
| Song, Z | 1 |
| Chu, S | 1 |
| Tao, J | 1 |
| Qian, Y | 1 |
| Malato, A | 1 |
| Rossi, E | 2 |
| Palumbo, GA | 1 |
| Guglielmelli, P | 2 |
| Pugliese, N | 1 |
| Brown, H | 1 |
| Lamrock, E | 1 |
| Bulte, CA | 1 |
| Hoegler, KM | 1 |
| Kutlu, Ö | 1 |
| Khachemoune, A | 1 |
| Hobbs, LK | 1 |
| Carr, PC | 1 |
| Gru, AA | 1 |
| Flowers, RH | 1 |
| Huang, YJ | 1 |
| Gao, Y | 1 |
| Wang, CJ | 1 |
| Han, DX | 1 |
| Zheng, Y | 1 |
| Wang, WH | 1 |
| Jiang, H | 1 |
| Yuan, B | 1 |
| Zhang, JB | 1 |
| Neill, B | 1 |
| Ryser, T | 1 |
| Neill, J | 1 |
| Aires, D | 1 |
| Rajpara, A | 1 |
| Saito, A | 1 |
| Fujisawa, Y | 1 |
| Maruyama, H | 1 |
| Nakamura, Y | 1 |
| Ishitsuka, Y | 1 |
| Watanabe, R | 1 |
| Okiyama, N | 1 |
| Fujimoto, M | 1 |
| Cantisani, C | 1 |
| Kiss, N | 1 |
| Naqeshbandi, AF | 1 |
| Tosti, G | 1 |
| Tofani, S | 1 |
| Cartoni, C | 1 |
| Carmosino, I | 1 |
| Cantoresi, F | 1 |
| Kumar, V | 1 |
| Jain, N | 1 |
| Chaudhary, SC | 1 |
| Mishra, S | 1 |
| Verner, E | 1 |
| Forsyth, C | 1 |
| Grigg, A | 1 |
| Wang, S | 1 |
| Xu, H | 1 |
| Liu, Y | 1 |
| He, W | 1 |
| Wang, W | 1 |
| Antar, A | 1 |
| Ishak, RS | 1 |
| Otrock, ZK | 1 |
| El-Majzoub, N | 1 |
| Ghosn, S | 1 |
| Mahfouz, R | 1 |
| Taher, AT | 1 |
| Koch, L | 1 |
| Lichem, R | 1 |
| Cerroni, L | 1 |
| Aberer, W | 1 |
| Massone, C | 1 |
| Mokni, S | 1 |
| Fetoui Ghariani, N | 1 |
| Aounallah, A | 1 |
| Fathallah, N | 1 |
| Boussofara, L | 1 |
| Saidi, W | 1 |
| Ben Salem, C | 1 |
| Sriha, B | 1 |
| Belajouza, C | 1 |
| Denguezli, M | 1 |
| Ghariani, N | 1 |
| Nouira, R | 1 |
| Saraceno, R | 1 |
| Teoli, M | 1 |
| Chimenti, S | 1 |
| Wiechert, A | 1 |
| Reinhard, G | 1 |
| Tüting, T | 1 |
| Uerlich, M | 1 |
| Bieber, T | 1 |
| Wenzel, J | 1 |
| Fegn, L | 1 |
| Wang, Z | 1 |
| Hoff, NP | 1 |
| Akanay-Diesel, S | 1 |
| Pippirs, U | 1 |
| Schulte, KW | 1 |
| Hanneken, S | 1 |
| Turner, ML | 1 |
| Schleußinger, TM | 1 |
| Dyall-Smith, D | 1 |
| Field, LM | 1 |
| Radić, J | 1 |
| Batinac, T | 1 |
| Hadžisejdić, I | 1 |
| Načinović-Duletić, A | 1 |
| Valković, T | 1 |
| Jonjić, N | 1 |
| Stone, T | 1 |
| Berger, A | 1 |
| Blumberg, S | 1 |
| O'Neill, D | 1 |
| Ross, F | 1 |
| McMeeking, A | 1 |
| Chen, W | 1 |
| Pastar, I | 1 |
| Antonioli, E | 1 |
| Pieri, L | 1 |
| Finazzi, M | 1 |
| Rumi, E | 1 |
| Martinelli, V | 1 |
| Vianelli, N | 1 |
| Luigia Randi, M | 1 |
| Bertozzi, I | 1 |
| De Stefano, V | 1 |
| Za, T | 1 |
| Ruggeri, M | 1 |
| Elli, E | 1 |
| Cacciola, R | 1 |
| Cacciola, E | 1 |
| Pogliani, E | 1 |
| Rodeghiero, F | 1 |
| Baccarani, M | 1 |
| Passamonti, F | 1 |
| Finazzi, G | 1 |
| Rambaldi, A | 1 |
| Bosi, A | 1 |
| Cazzola, M | 1 |
| Barbui, T | 1 |
| Vannucchi, AM | 1 |
| Pamuk, GE | 1 |
| Turgut, B | 1 |
| Vural, O | 1 |
| Demir, M | 1 |
| Tek, M | 1 |
| Altaner, S | 1 |
| Sanchez-Palacios, C | 1 |
| Guitart, J | 1 |
| Costanzi, JJ | 2 |
| Fletcher, WS | 1 |
| Balcerzak, SP | 1 |
| Taylor, S | 1 |
| Eyre, HJ | 1 |
| O'Bryan, RM | 1 |
| Al-Sarraf, M | 1 |
| Frank, J | 1 |
| Hill, GJ | 1 |
| Krementz, ET | 1 |
| Hill, HZ | 1 |
| Kinzel, V | 2 |
| Loehrke, H | 2 |
| Goerttler, K | 1 |
| Fürstenberger, G | 2 |
| Marks, F | 2 |
| Klemm-Mayer, H | 1 |
| Rasokat, H | 1 |
| Wagner, G | 1 |
| Iversen, OH | 2 |
| Ringborg, U | 2 |
| Lagerlöf, B | 1 |
| Lambert, B | 2 |
| Zietz, S | 1 |
| Lessin, S | 1 |
| Grattarola, M | 1 |
| Desaive, C | 1 |
| Nicolini, C | 1 |
| Lindelöf, B | 1 |
| Sigurgeirsson, B | 1 |
| Papi, M | 2 |
| Didona, B | 2 |
| DePità, O | 1 |
| Abruzzese, E | 2 |
| Stasi, R | 2 |
| Papa, G | 2 |
| Cavalieri, R | 2 |
| Angeli-Besson, C | 1 |
| Koeppel, MC | 1 |
| Jacquet, P | 1 |
| Andrac, L | 1 |
| Sayag, J | 1 |
| Callot-Mellot, C | 1 |
| Bodemer, C | 1 |
| Chosidow, O | 1 |
| Frances, C | 1 |
| Azgui, Z | 1 |
| Varet, B | 1 |
| de Prost, Y | 1 |
| Gerritsen, RJ | 1 |
| Teske, E | 1 |
| Kraus, JS | 1 |
| Rutteman, GR | 1 |
| Salmon-Ehr, V | 1 |
| Grosieux, C | 1 |
| Potron, G | 1 |
| Kalis, B | 1 |
| De Simone, C | 1 |
| Guerriero, C | 1 |
| Guidi, B | 1 |
| Rotoli, M | 1 |
| Venier, A | 1 |
| Tartaglione, R | 1 |
| Best, PJ | 1 |
| Petitt, RM | 1 |
| Ablett, E | 1 |
| Pedley, J | 1 |
| Dannoy, PA | 1 |
| Sturm, RA | 1 |
| Parsons, PG | 1 |
| Young, HS | 1 |
| Khan, AS | 1 |
| Kendra, JR | 1 |
| Coulson, IH | 1 |
| Aste, N | 1 |
| Fumo, G | 1 |
| Biggio, P | 1 |
| Estève, E | 1 |
| Georgescu, V | 1 |
| Heitzmann, P | 1 |
| Martin, L | 1 |
| Tam, DW | 1 |
| Van Scott, EJ | 1 |
| Urbach, F | 1 |
| Hunter, JA | 1 |
| Swanbeck, G | 1 |
| Aranha, GV | 1 |
| Grage, TB | 1 |
| Wollner, N | 1 |
| Lieberman, P | 1 |
| Exelby, P | 1 |
| D'angio, G | 1 |
| Burchenal, J | 1 |
| Fang, S | 1 |
| Murphy, ML | 1 |
| Vaitkevicius, VK | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 1 |
| Luce, JK | 2 |
| Cantonetti, M | 1 |
| Castel, T | 1 |
| Estapé, J | 1 |
| Viñolas, N | 1 |
| Mascaró, JM | 1 |
| Castro, J | 1 |
| Vilalta, A | 1 |
| Gratacós, R | 1 |
| Daniels, M | 1 |
| Palou, J | 1 |
| Grau, JJ | 1 |
| Barnhill, RL | 1 |
| Wiles, JC | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| McPherson, TA | 1 |
| Berk, PD | 1 |
| Goldberg, JD | 1 |
| Donovan, PB | 1 |
| Fruchtman, SM | 1 |
| Berlin, NI | 1 |
| Wasserman, LR | 1 |
| Wagenknecht, L | 2 |
| McDonald, CJ | 1 |
| Dantzig, PI | 1 |
| Stephens, FO | 1 |
| Sugiura, K | 1 |
| Johnson, FD | 1 |
| Jacobs, EM | 1 |
| Seiji, M | 1 |
| Takahashi, M | 1 |
| Laugier, P | 1 |
| Orusco, M | 1 |
| Jaccard, MA | 1 |
| Hennings, H | 2 |
| Michael, D | 1 |
| Patterson, E | 1 |
| Gottlieb, JA | 1 |
| Frei, E | 1 |
| Chan, PC | 1 |
| Goldman, A | 1 |
| Wynder, EL | 1 |
| Willbanks, OL | 1 |
| Fogelmann, MJ | 1 |
| Smith, HC | 1 |
| Boutwell, RK | 1 |
| Potter, VR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241] | Phase 2 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for hydroxyurea and Cancer of Skin
| Article | Year |
|---|---|
Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Topics: Humans; Hydroxyurea; Interferons; Janus Kinase Inhibitors; Keratosis, Actinic; Myeloproliferative Di | 2020 |
Hydroxyurea: a reappraisal of its cutaneous side effects and their management.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Hyperpigmentation; Leg Ulcer; Skin; Skin Neoplasms | 2021 |
Case and review: Cutaneous involvement by chronic neutrophilic leukemia vs Sweet syndrome- A diagnostic dilemma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Decitabine; Diagnosis, Di | 2021 |
Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience.
Topics: Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Hydroxyurea; Male; Photochemotherapy; Poly | 2019 |
Hydroxyurea-associated squamous dysplasia.
Topics: Aged; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Keratosis; Male; Precancerous Conditions; Skin | 2004 |
Cutaneous carcinoma during long-term hydroxyurea therapy: a report of 5 cases.
Topics: Aged; Female; Humans; Hydroxyurea; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Skin Neopla | 1996 |
Cutaneous malignant melanoma.
Topics: Adult; Aged; Biopsy; Carmustine; Cyclophosphamide; Dactinomycin; Female; Humans; Hydroxyurea; Male; | 1976 |
Immunosuppressive and cytotoxic drugs in dermatology.
Topics: Animals; Antineoplastic Agents; Azathioprine; Azauridine; Bleomycin; Chlorambucil; Cyclophosphamide; | 1974 |
5 trials available for hydroxyurea and Cancer of Skin
| Article | Year |
|---|---|
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; D | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Ultraviolet-induced dna repair synthesis in lymphocytes from patients with actinic keratosis.
Topics: Aged; Clinical Trials as Topic; DNA Repair; DNA Replication; Dose-Response Relationship, Radiation; | 1976 |
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Combined Modality Therapy; | 1991 |
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Topics: Acute Disease; Age Factors; Bloodletting; Chlorambucil; Combined Modality Therapy; False Positive Re | 1986 |
64 other studies available for hydroxyurea and Cancer of Skin
| Article | Year |
|---|---|
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Incidence; Janus Kin | 2021 |
Utility of Optical Imaging in a Patient With Recurrent, Multifocal Hydroxyurea-Associated Basal Cell Carcinoma.
Topics: Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Middle Aged; Neoplasm R | 2022 |
Angiokeratoma-like purpuric palmar nodules following chemotherapy.
Topics: Angiokeratoma; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, | 2021 |
Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera.
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Male; Nitriles; Polycythemia Vera; | 2022 |
Successful management of hydroxyurea-induced multiple actinic keratoses and cutaneous squamous cell carcinomas with combination treatment.
Topics: Carcinoma, Squamous Cell; Humans; Hydroxyurea; Keratosis, Actinic; Skin Neoplasms | 2023 |
Hydroxyurea-induced squamous cell carcinoma.
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; Neoplasms, Multiple Primar | 2021 |
Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation; | 2021 |
A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea.
Topics: Aged; Biopsy; Carcinoma, Squamous Cell; Dermatomyositis; Humans; Hydroxyurea; Keratosis; Male; Polyc | 2017 |
Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
Topics: Aged; Female; Humans; Hydroxyurea; Hyperpigmentation; Melanoma; Nail Diseases; Nucleic Acid Synthesi | 2018 |
Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, | 2013 |
Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Chro | 2014 |
Leukaemia cutis as the initial manifestation in a child with brachydactyly in chronic phase of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Brachydactyly; Child; Diagnosis, Differential; Fingers; Humans; Hydroxyurea; | 2014 |
Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chronic Disease; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Skin | 2014 |
Dermatitis, nonmelanoma skin cancer and leg ulcers.
Topics: Aged, 80 and over; Antineoplastic Agents; Dermatomyositis; Female; Humans; Hydroxyurea; Keratosis, A | 2016 |
[Dermatologic complications of long-term hydroxyurea therapy].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Keratosis, Actinic; Male; Midd | 2017 |
Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject.
Topics: Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxy | 2008 |
[Multiple skin cancers in a patient treated with hydroxyurea].
Topics: Adult; Antineoplastic Agents; Humans; Hydroxyurea; Male; Neoplasms, Multiple Primary; Skin Neoplasms | 2009 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy | 2009 |
[Cutaneous side effects of hydroxyurea treatment for polycythemia vera].
Topics: Aged; Antisickling Agents; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Hydroxyurea; Le | 2009 |
Sun, drugs, and skin cancer: a continuing saga.
Topics: Aged, 80 and over; Disease Progression; Female; Humans; Hydroxyurea; Neoplasms, Radiation-Induced; N | 2010 |
Hydroxyurea-associated squamous dysplasia in a monozygotic twin.
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Diseases in Twins; Facial Dermatoses; Female; Hand Derm | 2011 |
Concurrent basal cell and squamous cell carcinomas associated with hydroxyurea therapy.
Topics: Aged; Antimetabolites; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; | 2011 |
A multidisciplinary team approach to hydroxyurea-associated chronic wound with squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chronic Disease; Debridement; Female; Humans; Hydro | 2012 |
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Carcinoma, Squamous Cell; Drug Eruptions; Female; F | 2012 |
Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Leukemia, Myelogenous, C | 2003 |
Suppression of the first stage of phorbol 12-tetradecanoate 13-acetate-effected tumor promotion in mouse skin by nontoxic inhibition of DNA synthesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cell Transformation, Neoplastic; DNA Replication; Female; | 1984 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female | 1984 |
Enhancement of methylnitrosourea skin carcinogenesis by inhibiting cell proliferation with hydroxyurea or skin extracts.
Topics: Animals; Cell Division; DNA; Female; Hydroxyurea; Male; Methylnitrosourea; Mice; Mice, Inbred Strain | 1982 |
Hydroxyurea enhances methylnitrosourea skin tumorigenesis when given shortly before, but not after, the carcinogen.
Topics: Animals; DNA; Hydroxyurea; Methylnitrosourea; Mice; Mice, Inbred Strains; Neoplasms, Experimental; N | 1982 |
Normal UV-induced DNA repair synthesis in peripheral leukocytes from patients with malignant melanoma of the skin.
Topics: Aged; DNA Repair; Dose-Response Relationship, Radiation; Humans; Hydroxyurea; In Vitro Techniques; L | 1980 |
FPi analysis. II. Use of the method to monitor the in vivo kinetics of cell populations perturbed by hydroxyurea.
Topics: Animals; Bone Marrow; Cell Division; Hydroxyurea; Lung Neoplasms; Mathematics; Melanoma; Mice; Mice, | 1980 |
PUVA and cancer: a case-control study.
Topics: Adult; Aged; Arsenic; Carcinoma, Squamous Cell; Case-Control Studies; Coal Tar; Combined Modality Th | 1993 |
Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Leukemia, Myelogenous, C | 1993 |
Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydr | 1995 |
Multi-agent chemotherapy for mast cell tumours in the dog.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 1998 |
Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment.
Topics: Aged; Antineoplastic Agents; Busulfan; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydr | 1998 |
Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Face; Humans; Hydroxyurea; Leukemia, Myelogen | 1998 |
Multiple skin cancers associated with hydroxyurea therapy.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; Middle Aged; Neoplasms | 1998 |
UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma.
Topics: Antineoplastic Agents; beta-Galactosidase; Cell Cycle; Cisplatin; Demecolcine; Genes, fos; Genes, p5 | 1998 |
The cutaneous side-effects of hydroxyurea.
Topics: Aged; Alopecia; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; Keratosis; Polycythemia Vera; | 2000 |
Multiple squamous epitheliomas during long-term treatment with hydroxyurea.
Topics: Carcinoma, Squamous Cell; Humans; Hydroxyurea; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; | 2001 |
[Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea].
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; Mouth Neoplasms; Neo | 2001 |
Bowen's disease and squamous cell carcinoma. Occurrence in a patient with psoriasis after topical, systemic, and PUVA therapy.
Topics: Adult; Carcinoma, Squamous Cell; Coal Tar; Cocarcinogenesis; Glucocorticoids; Humans; Hydroxyurea; M | 1979 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Child; Child, Preschool; Cyclophosp | 1975 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Multiple skin tumors in long-term treatment with hydroxyurea.
Topics: Aged; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Skin Neoplasms | 1992 |
Malignant melanoma associated with multiple therapies for psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Coal Tar; Humans; Hydroxyurea; Male; Melanoma; Methotrexate; Photoch | 1989 |
Three-stage tumorigenesis in mouse skin: DNA synthesis as a prerequisite for the conversion stage induced by TPA prior to initiation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cocarcinogenesis; DNA; Female; Hydroxyurea; Mice; Mice, I | 1986 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
[Chemotherapy of malignant melanoma].
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Bleomycin; Carmustine; Cyclohexanes; Drug Therapy, | 1973 |
Cutaneous uses of the antiproliferative drugs.
Topics: Administration, Topical; Antimetabolites; Azauridine; Bleomycin; Chemical and Drug Induced Liver Inj | 1974 |
Combined chemotherapy, radiotherapy, and surgery in the treatment of advanced but localized solid malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cystadenocarcinoma; Drug Th | 1974 |
Chemotherapy of induced skin tumors in mice.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Benz(a)Anthracenes; Busulfan; Ca | 1968 |
Chemotherapy of metastatic malignant melanoma. Experience with 73 patients.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Colchicine; Cyclophosphamide; Cytarabine; Eye Neop | 1971 |
Malignant melanoma with adjacent intraepidermal proliferation.
Topics: Adult; Chromomycin A3; Ethnicity; Female; Heel; Humans; Hydroxyurea; Lentigo; Lip Neoplasms; Lung Ne | 1974 |
[Polychemotherapy of metastatic melanoma. Preliminary report].
Topics: Adult; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Co | 1972 |
Enhancement of skin tumorigenesis by a single application of croton oil before or soon after initiation by urethan.
Topics: Animals; Cell Division; Croton Oil; DNA; DNA Replication; Female; Hydroxyurea; Mice; Neoplasms, Expe | 1973 |
Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma.
Topics: Administration, Oral; Adult; Amides; Female; Humans; Hydroxyurea; Imidazoles; Injections, Intravenou | 1971 |
Hydroxyurea: suppression of two-stage carcinogensis in mouse skin.
Topics: Animals; Croton Oil; Hydroxyurea; Mice; Neoplasms, Experimental; Papilloma; Skin Neoplasms | 1970 |
Gastrointestinal melanosarcoma.
Topics: Adult; Aged; Biopsy; Colostomy; Female; Follow-Up Studies; Humans; Hydroxyurea; Intestinal Neoplasms | 1970 |
Hydroxyurea: possible relationship of cytotoxicity to inhibition of skin carcinogenesis.
Topics: Animals; Carcinogens; Croton Oil; DNA; DNA, Neoplasm; Female; Hydroxyurea; Injections, Intraperitone | 1971 |
Effects of hydroxyurea on DNA and RNA synthesis in mouse skin, liver, and thymus and on skin tumorigenesis initiated by beta-propiolactone.
Topics: Animals; DNA Replication; Hydroxyurea; Injections, Intraperitoneal; Lactones; Liver; Mice; Propionat | 1968 |